Articles tagged "Post-transplant malignancy"

2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
E. Rondeau,¹ E. Cassuto,² V. Vuiblet,³ C. Legendre,⁴ P. Merville,⁵ Y. Le Meur,⁶ B. Moulin,⁷ P. Westeel,⁸ B. Hurault De Ligny,⁹ A. Lécuyer,¹⁰ M. Tindel,¹¹ N. Kamar.¹²
¹Hôpital Tenon, Paris, France; ²Hôpital Pasteur, Nice, France; ³Hôpital Maison Blanche, Reims, France; ⁴Hôpital Necker, Paris, France; ⁵Hôpital Pellegrin, Bordeaux, France; ⁶Hôpital La Cavale Blanche, Brest, France; ⁷Nouvel Hôpital Civil, Strasbourg, France; ⁸Hôpital Sud, Amiens, France; ⁹CHU, Caen, France; ¹⁰Novartis Pharma S.A.S, Rueil-Malmaison, France; ¹¹Keyrus Biopharma, Levallois-Perret, France; ¹²Hôpital Rangueil, Toulouse, France.
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…
2015 American Transplant Congress
Verification of OPTN Hepatocellular Carcinoma Recurrence Data
J. George,¹ K. Eddinger,¹ D. Goldberg,² M. Levine,³ P. Abt.³
¹Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA; ³Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
PURPOSE: OPTN data on HCC recurrence is increasingly utilized for a variety of studies; however, the accuracy of this data has not been examined. We…
2015 American Transplant Congress
Cancer Mortality Among Recipients of Solid Organ Transplant in Ontario
S. Acuna,^1,2,3 K. Fernandes,⁴ C. Daly,^2,3 L. Hicks,³ R. Sutradhar,^1,4 S. Kim,^1,4 N. Baxter.^1,2,3,4
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ³Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Purpose: Solid organ transplantation recipients (SOTR) have a higher risk of some cancers than the general population, but are also at high risk of mortality…